$MYO

KIRK THOMAS F purchased $25K of MYO

KIRK THOMAS F purchased 25,000 shares of MYOMO, INC. (MYO) at $0.99 on 2026-05-28.

Original reporting
SEC EDGAR · KIRK THOMAS F
Published Jun 1, 2026, 12:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 12:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MYO
Bullish
medium confidence
Mentioned
$MYO
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MYOBullishLow
01

Why it matters

A director’s open-market purchase is a new, specific datapoint, but it typically carries limited predictive power without concurrent company-specific news.

02

Market read

Traders may view the buy as modestly supportive, but without additional catalysts it is unlikely to drive sustained repricing.

03

What to watch

Check whether the director has a pattern of buys/sells and whether the purchase size is meaningful versus prior holdings; absence of a 10b5-1 plan reduces predictability but not necessarily conviction.

Relevance 7/10Novelty 8/10Timing: today’s SEC Form 4 filing (filed 2026-06-01) for a 2026-05-28 buy

Background

The article is an SEC Form 4 insider transaction disclosure for MYOMO, Inc. (MYO).

Company-level read

Ticker impact

$MYOBullishMedium confidence
Context

Insider/director open-market purchase disclosed via SEC Form 4: 25,000 shares bought at $0.9930 on 2026-05-28.

Expected impact

Low, near-term impact at most; any move would be sentiment-driven and should fade without new company news.

Evidence & confidence

This is an ownership-change disclosure (Form 4) with no accompanying operational or financial catalyst, so it typically has modest standalone trading effect.

Market effects

Minimal; single-company insider transaction without sector-wide signal.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (compensation, liquidity planning) and may not reflect near-term upside catalysts.

Key entities

  • MYOMO, Inc.

    Subject of the SEC Form 4 insider transaction disclosure.

  • Kirk Thomas F

    Director who purchased 25,000 shares of MYO at $0.9930/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MYOMedAI 8/10

Myomo Q2 Earnings Call Highlights

Myomo (MYO) said MyoConnect referrals rose to 17% of Q2 pipeline additions from 11% in Q1. Of 739 patients added, about 122 came from referrals. Gross margin increased to 72.1% from 62.7%. Q2 net loss was $4.0M ($0.09/share). Q3 revenue guidance is $11.5M to $12.0M, and full-year revenue outlook raised to $45M to $47M.

$MYOHigh

MYOMO, INC. (MYO): Results of Operations and Financial Condition

MYOMO, INC. (MYO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Myomo Reports Second Quarter 2026 Financial and Operating Results Revenue of $11.7 million, increased 21% year over year Four success pillars driving higher revenue growth and operating leverage Raising full year revenue guidance to $45-47 million Conference call beg

$RGNTMedAI 8/10

Top Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR's Maggot Therapy, MYO On Watch

Regentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.

$PBLSMed

Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch

Biotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.